secwatch.observer — SEC 8-K summary
======================================

Issuer:     DURECT CORP (—)
CIK:        0001082038
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0000950170-24-037198
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DURECT reports Q4/FY2023 results; larsucosterol shows mortality reduction in Phase 2b AH trial
--------------------------------------------------------------------------------

- Q4 2023 total revenues $2.7M, net loss $1.4M vs $3.3M and $10.5M in Q4 2022.
- Full year 2023 revenues $8.5M, net loss $27.6M vs $19.3M and $35.3M in 2022; cash $29.8M.
- Larsucosterol 30mg reduced 90-day mortality 41% (p=0.068); 90mg reduced 35% (p=0.124).
- In U.S. patients, mortality reductions of 57% (30mg, p=0.014) and 58% (90mg, p=0.008).
- Entered co-marketing agreement with Charles River for ALZET osmotic pumps in U.S./Canada.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082038/000095017024037198/0000950170-24-037198-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082038/000095017024037198/drrx-20240327.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-037198

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer